Phathom Pharmaceuticals (PHAT) Other Accumulated Expenses (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Other Accumulated Expenses data on file, last reported at $5.6 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 99.5% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 99.5% increase from a year earlier, with the FY2025 full-year figure at $7.5 million, up 146.39% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $5.6 million, down from $7.5 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for PHAT reached as high as $7.5 million in Q4 2025 and fell as low as $20000.0 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $1.9 million across 5 years, with a median of $726000.0 in 2024.
• Across the five-year window, Other Accumulated Expenses plunged 46.15% in 2023 and surged 8865.0% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $151000.0 in 2022, then retreated by 22.52% to $117000.0 in 2023, then soared by 2501.71% to $3.0 million in 2024, then surged by 146.39% to $7.5 million in 2025, then retreated by 25.17% to $5.6 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $5.6 million in Q1 2026, $7.5 million in Q4 2025, and $4.8 million in Q3 2025.